Hosted by the MRC Integrative Epidemiology Unit (IEU)
Brief abstract: Human genetics has become an increasingly popular means of identifying modifiable therapeutic targets for disease. For the last 16 months, I have been working at a start-up that partners with biotech, venture capital and pharma companies to interrogate their drug candidates and identify new ones using human genetic and multi-omic data. This experience has sharpened my perspective on the value of human genetics in this space. I will share some projects from the last year that I believe highlight the scientific (and, in some cases, very human) challenges and potential of genetics-based drug discovery. Any client confidential information will be withheld to ensure compliance with all relevant CDAs.
Biography: Matt Tudball is an Associate Principal Scientist at 5 Prime Sciences, where he is responsible for leading scientific programmes to identify and validate therapeutic targets using human genetic and multi-omic data. Before joining 5 Prime, Matt completed his PhD at the IEU developing novel causal and statistical inference methods for sample selection bias and Mendelian randomization.